手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| ベイズ型第I相臨床試験× | ベイズ的無作為化臨床試験× | |
|---|---|---|
| 分野 | 疫学 | 疫学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1990 | 1980s–2000s (formal methodology consolidated ~2004–2006) |
| 提唱者≠ | O'Quigley, Pepe & Fisher (Continual Reassessment Method) | Donald A. Berry and David J. Spiegelhalter (applied Bayesian inference formally to RCT design) |
| 種類≠ | Adaptive Bayesian dose-finding design | Randomized experimental study with Bayesian inference |
| 原典≠ | O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗ | Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley. ISBN: 978-0471499756 |
| 別名 | Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study | Bayesian RCT, Bayesian adaptive trial, Bayesian clinical trial design, BRCT |
| 関連 | 5 | 5 |
| 概要≠ | A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses. | A Bayesian randomized clinical trial (Bayesian RCT) combines the rigour of random treatment allocation with Bayesian statistical inference, allowing researchers to incorporate prior evidence and update beliefs continuously as trial data accumulate. Unlike the classical frequentist RCT, it yields direct probability statements about treatment effects and supports pre-specified adaptive stopping rules based on posterior probabilities. |
| ScholarGateデータセット ↗ |
|
|